Impact of gender-affirming hormone therapy on dry eye
Journal of Clinical & Translational Endocrinology · 2026-08 · 45 · 100451
DOI: 10.1016/j.jcte.2026.100451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical & Translational Endocrinology, 2026-08. Verfasst von Keith E Arnold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Cleveland, OH, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Purpose
To determine whether gender-affirming hormone therapy (GAHT) influences tear system health in transgender individuals.
Methods
This retrospective cohort observational study analyzed data from transgender men and women ages ≥18-years between 2004 and 2024 via electronic medical record (EMR) data. Following propensity score matching, subjects on hormone therapy included 23,623 transgender men, 15,933 transgender women, and an equal number in each matched control group.
Results
Among transgender men and women, respectively, tear system disorders occurred in 0.90% and 0.94% of those using GAHT and 0.90% and 1.17% of those not using GAHT ( p = 0.211 and 0.072). There was no significant difference in those with documented utilization of GAHT versus no GAHT, for both transgender men and women, respectively, in lacrimal system disorder ( p = 0.427, p = 0.292), meibomian gland dysfunction ( p = 0.687, p = 0.255), keratoconjunctivitis sicca ( p = 0.685, p = 0.576), and combined tear disorders ( p = 0.527, p = 0.168).
Conclusions
In this cohort, EMR-documented masculinizing or feminizing GAHT was not associated with an increased incidence of recorded tear-system disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Department of Ophthalmology, Eastern Virginia Medical School at Old Dominion University, Norfolk, Virginia, USA.
- Department of Urology, MetroHealth Medical Center, Cleveland, OH, USA.
Förderung
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Arnold, K. E., Foster, M. J., Tabernacki, T. A., Turner, C. A., Netland, P. A., & Mishra, K. (2026). Impact of gender-affirming hormone therapy on dry eye. Journal of Clinical & Translational Endocrinology, 45, 100451. https://doi.org/10.1016/j.jcte.2026.100451
Vancouver
Arnold KE, Foster MJ, Tabernacki TA, Turner CA, Netland PA, Mishra K. Impact of gender-affirming hormone therapy on dry eye. Journal of Clinical & Translational Endocrinology. 2026;45:100451. doi:10.1016/j.jcte.2026.100451
BibTeX
@article{Arnold2026,
author = {Arnold, Keith E and Foster, Michael J and Tabernacki, Tomasz A and Turner, Chase A and Netland, Peter A and Mishra, Kirtishri},
title = {Impact of gender-affirming hormone therapy on dry eye},
journal = {Journal of Clinical & Translational Endocrinology},
year = {2026},
volume = {45},
pages = {100451},
doi = {10.1016/j.jcte.2026.100451}
}
EUVIMED